VERV - Verve Therapeutics GAAP EPS of -$0.59 beats by $0.12 revenue of $5.7M beats by $3.45M
2024-05-08 11:23:21 ET
More on Verve Therapeutics
- Verve Therapeutics: An Update On Human CRISPR
- Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
- Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
- Verve drops after pausing trial enrollments for lead asset
- Seeking Alpha’s Quant Rating on Verve Therapeutics